1 Alok K. Tewari, MD, PhD, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Silke Gillessen, MD, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Università della Svizzera Italiana, Lugano, Switzerland, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom; and Christopher J. Sweeney, MBBS, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.